Kelly, William K.

Histone deacetylases and cancer: causes and therapies

Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 1,866

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 461

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., & Schwartz, M. (1997) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 227

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Siefker-Radtke, A. O., Currie, G., Abella, E., Vaena, D. A., Rezazadeh Kalebasty, A., Curigliano, G., Tupikowski, K., Andric, Z. G., Lugowska, I., & Kelly, W. K. (2019) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor Research

Cited by 64

STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and Their Clinical Implications for Prostate Cancer

Xu, M., Evans, L., Bizzaro, C. L., Quaglia, F., Verrillo, C. E., Li, L., Stieglmaier, J., Schiewer, M. J., Languino, L. R., & Kelly, W. K. (2022) · Cancers

Prostate Cancer Treatment and ResearchProtease and Inhibitor Mechanisms

Cited by 61